Immune Monitoring upon Treatment with Biologics in Sjögren’s Syndrome: The What, Where, When, and How

Immune Monitoring upon Treatment with Biologics in Sjögren’s Syndrome: The What, Where, When, and How

Over the years, a wide variety of therapeutic antibodies has been successfully introduced in the auto-immunology clinic, and many more are on the way. Many of these treatments address either a pathogenic circulating molecule or a cell-bound molecule. Whereas addressing the former target results in n...

Full description

Bibliographic Details
Main Authors: Joyce J.B.C. van Beers, Jan G.M.C. Damoiseaux
Format: Article
Language:English
Published: MDPI AG 2021-01-01
Series:Biomolecules
Subjects:
immune monitoring
biologics
<i>Sjögren’s</i> syndrome
<i>Sjögren’s</i> disease
Online Access:https://www.mdpi.com/2218-273X/11/1/116
id doaj-c38523a087ae4beb982e9b6a7a3b20ff
record_format Article
spelling doaj-c38523a087ae4beb982e9b6a7a3b20ff2021-01-17T00:03:35ZengMDPI AGBiomolecules2218-273X2021-01-011111611610.3390/biom11010116Immune Monitoring upon Treatment with Biologics in Sjögren’s Syndrome: The What, Where, When, and HowJoyce J.B.C. van Beers0Jan G.M.C. Damoiseaux1Central Diagnostic Laboratory Maastricht University Medical Center, Laboratory Specialist in Medical Immunology and Clinical Chemistry, 6202 AZ Maastricht, The NetherlandsCentral Diagnostic Laboratory Maastricht University Medical Center, Laboratory Specialist in Medical Immunology, 6202 AZ Maastricht, The NetherlandsOver the years, a wide variety of therapeutic antibodies has been successfully introduced in the auto-immunology clinic, and many more are on the way. Many of these treatments address either a pathogenic circulating molecule or a cell-bound molecule. Whereas addressing the former target results in neutralization of the soluble factor and binding to the latter target either inhibits cellular function or induces selective cell death. If this targeted molecule or cell is part of the immune system, this therapy evokes a state of immunodeficiency with infections as a possible consequence. Therefore, immune monitoring is needed to prevent such adverse side effects of immunotherapy. In this paper, different immunotherapies used in <i>Sjögren’s</i> syndrome, as well as different approaches to monitoring the immune system, are discussed.https://www.mdpi.com/2218-273X/11/1/116immune monitoringbiologics<i>Sjögren’s</i> syndrome<i>Sjögren’s</i> disease
collection DOAJ
language English
format Article
sources DOAJ
author Joyce J.B.C. van Beers
Jan G.M.C. Damoiseaux
spellingShingle Joyce J.B.C. van Beers
Jan G.M.C. Damoiseaux
Immune Monitoring upon Treatment with Biologics in Sjögren’s Syndrome: The What, Where, When, and How
Biomolecules
immune monitoring
biologics
<i>Sjögren’s</i> syndrome
<i>Sjögren’s</i> disease
author_facet Joyce J.B.C. van Beers
Jan G.M.C. Damoiseaux
author_sort Joyce J.B.C. van Beers
title Immune Monitoring upon Treatment with Biologics in Sjögren’s Syndrome: The What, Where, When, and How
title_short Immune Monitoring upon Treatment with Biologics in Sjögren’s Syndrome: The What, Where, When, and How
title_full Immune Monitoring upon Treatment with Biologics in Sjögren’s Syndrome: The What, Where, When, and How
title_fullStr Immune Monitoring upon Treatment with Biologics in Sjögren’s Syndrome: The What, Where, When, and How
title_full_unstemmed Immune Monitoring upon Treatment with Biologics in Sjögren’s Syndrome: The What, Where, When, and How
title_sort immune monitoring upon treatment with biologics in sjögren’s syndrome: the what, where, when, and how
publisher MDPI AG
series Biomolecules
issn 2218-273X
publishDate 2021-01-01
description Over the years, a wide variety of therapeutic antibodies has been successfully introduced in the auto-immunology clinic, and many more are on the way. Many of these treatments address either a pathogenic circulating molecule or a cell-bound molecule. Whereas addressing the former target results in neutralization of the soluble factor and binding to the latter target either inhibits cellular function or induces selective cell death. If this targeted molecule or cell is part of the immune system, this therapy evokes a state of immunodeficiency with infections as a possible consequence. Therefore, immune monitoring is needed to prevent such adverse side effects of immunotherapy. In this paper, different immunotherapies used in <i>Sjögren’s</i> syndrome, as well as different approaches to monitoring the immune system, are discussed.
topic immune monitoring
biologics
<i>Sjögren’s</i> syndrome
<i>Sjögren’s</i> disease
url https://www.mdpi.com/2218-273X/11/1/116
work_keys_str_mv AT joycejbcvanbeers immunemonitoringupontreatmentwithbiologicsinsjogrenssyndromethewhatwherewhenandhow
AT jangmcdamoiseaux immunemonitoringupontreatmentwithbiologicsinsjogrenssyndromethewhatwherewhenandhow
_version_ 1724335670102589440

Similar Items